Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
United Therapeutics Stock Quote

United Therapeutics (NASDAQ: UTHR)

$231.78
(-1.4%)
-$3.30
Price as of April 16, 2024, 4:00 p.m. ET

United Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
UTHR +2.78% +133.56% +18.49% +3,758%
S&P +22.34% +74.52% +11.78% +278%

United Therapeutics Company Info

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

News & Analysis

The Fool has written over 100 articles on United Therapeutics.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.